Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study

IJC Metabolic and Endocrine

Volumn 5, Issue , 2014, Pages 11-18

  Gaggin, Hanna K ^a   Bhardwaj, Anju ^a   Belcher, Arianna M ^a   Motiwala, Shweta R ^a   Gandhi, Parul U ^a   Simon, Mandy L ^a   Kelly, Noreen P ^a   Anderson, Amanda M ^a   Garasic, Joseph M ^a   Danik, Stephan B ^a   Schwamm, Lee H ^a   Gerszten, Robert E ^a   van Kimmenade, Roland R J ^b   Januzzi, James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Catheterization; Coronary artery disease; Peripheral arterial disease; Renal disease; Stroke

Indexed keywords

BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEATH; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY;

EID: 84919499678     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2014.08.005     Document Type: Article

References (51)

1. Elixhauser A. United States. Agency for Healthcare Research and Quality. Procedures in U.S. hospitals, 1997 2001, Agency for Healthcare Research and Quality, Rockville, Md.
2. Cuddy E., Robertson S., Cross S., Isles C. Risks of coronary angiography. Lancet 2005, 366:1825.
3. Spoon D.B., Psaltis P.J., Singh M., Holmes D.R., Gersh B.J., Rihal C.S., et al. Trends in cause of death after percutaneous coronary intervention. Circulation 2014, 129:1286-1294.
4. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D. Third universal definition of myocardial infarction. J. Am. Coll. Cardiol. 2012, 60:1581-1598.
5. Moussa I.D., Klein L.W., Shah B., Mehran R., Mack M.J., Brilakis E.S., et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J. Am. Coll. Cardiol. 2013, 62:1563-1570.
6. Januzzi J.L., van Kimmenade R., Lainchbury J., Bayes-Genis A., Ordonez-Llanos J., Santalo-Bel M., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur. Heart J. 2006, 27:330-337.
7. Adams H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41.
8. Mehta R.L., Kellum J.A., Shah S.V., Molitoris B.A., Ronco C., Warnock D.G., et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 2007, 11:R31.
9. Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 2004, 8:R204-R212.
10. McCullough P.A., Adam A., Becker C.R., Davidson C., Lameire N., Stacul F., et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am. J. Cardiol. 2006, 98:5K-13K.
11. Fukumoto Y., Tsutsui H., Tsuchihashi M., Masumoto A., Takeshita A. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J. Am. Coll. Cardiol. 2003, 42:211-216.
12. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39:S1-266.
13. Rutherford R.B., Baker J.D., Ernst C., Johnston K.W., Porter J.M., Ahn S., et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J. Vasc. Surg. 1997, 26:517-538.
14. Noto T.J., Johnson L.W., Krone R., Weaver W.F., Clark D.A., Kramer J.R., et al. Cardiac catheterization 1990: a report of the Registry of the Society for Cardiac Angiography and Interventions (SCA&I). Catheter. Cardiovasc. Diagn. 1991, 24:75-83.
15. Maynard C., Chapko M.K., Every N.R., Martin D.C., Ritchie J.L. Coronary angioplasty outcomes in the Healthcare Cost and Utilization Project, 1993-1994. Am. J. Cardiol. 1998, 81:848-852.
16. Rihal C.S., Textor S.C., Grill D.E., Berger P.B., Ting H.H., Best P.J., et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105:2259-2264.
17. Rudnick M.R., Goldfarb S., Wexler L., Ludbrook P.A., Murphy M.J., Halpern E.F., et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995, 47:254-261.
18. Tommaso C.L. Contrast-induced nephrotoxicity in patients undergoing cardiac catheterization. Catheter. Cardiovasc. Diagn. 1994, 31:316-321.
19. Malenka D.J., O'Rourke D., Miller M.A., Hearne M.J., Shubrooks S., Kellett M.A., et al. Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty. The Northern New England Cardiovascular Disease Study Group. Am. Heart J. 1999, 137:632-638.
20. Pocock S.J., Ariti C.A., Collier T.J., Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur. Heart J. 2012, 33:176-182.
21. Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. J. Am. Coll. Cardiol. 2007, 50:2173-2195.
22. Prasad A., Singh M., Lerman A., Lennon R.J., Holmes D.R., Rihal C.S. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J. Am. Coll. Cardiol. 2006, 48:1765-1770.
23. Panteghini M., Pagani F., Yeo K.T., Apple F.S., Christenson R.H., Dati F., et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin. Chem. 2004, 50:327-332.
24. Macrae A.R., Kavsak P.A., Lustig V., Bhargava R., Vandersluis R., Palomaki G.E., et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin. Chem. 2006, 52:812-818.
25. Keller T., Zeller T., Ojeda F., Tzikas S., Lillpopp L., Sinning C., et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA 2011, 306:2684-2693.
26. Prasad A., Rihal C.S., Lennon R.J., Singh M., Jaffe A.S., Holmes D.R. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ. Cardiovasc. Interv. 2008, 1:10-19.
27. Nienhuis M.B., Ottervanger J.P., Dikkeschei B., Suryapranata H., de Boer M.J., Dambrink J.H., et al. Prognostic importance of troponin T and creatine kinase after elective angioplasty. Int. J. Cardiol. 2007, 120:242-247.
28. Januzzi J.L., Camargo C.A., Anwaruddin S., Baggish A.L., Chen A.A., Krauser D.G., et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 2005, 95:948-954.
29. James S.K., Lindahl B., Siegbahn A., Stridsberg M., Venge P., Armstrong P., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003, 108:275-281.
30. Kragelund C., Gronning B., Kober L., Hildebrandt P., Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N. Engl. J. Med. 2005, 352:666-675.
31. Foote R.S., Pearlman J.D., Siegel A.H., Yeo K.T. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J. Am. Coll. Cardiol. 2004, 44:1980-1987.
32. Bhardwaj A., Truong Q.A., Peacock W.F., Yeo K.T., Storrow A., Thomas S., et al. A multicenter comparison of established and emerging cardiac biomarkers for the diagnostic evaluation of chest pain in the emergency department. Am. Heart J. 2011, 162:276-82 e1.
33. Omland T., Sabatine M.S., Jablonski K.A., Rice M.M., Hsia J., Wergeland R., et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J. Am. Coll. Cardiol. 2007, 50:205-214.
34. Bashore T.M., Gehrig T. Cholesterol emboli after invasive cardiac procedures. J. Am. Coll. Cardiol. 2003, 42:217-218.
35. Lindsay J., Apple S., Pinnow E.E., Gevorkian N., Gruberg L., Satler L.F., et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter. Cardiovasc. Interv. 2003, 59:338-343.
36. Spanaus K.S., Kollerits B., Ritz E., Hersberger M., Kronenberg F., von Eckardstein A. Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin. Chem. 2010, 56:740-749.
37. Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 2002, 40:221-226.
38. Herget-Rosenthal S. One step forward in the early detection of acute renal failure. Lancet 2005, 365:1205-1206.
39. Rinder C.S., Fontes M., Mathew J.P., Rinder H.M., Smith B.R. Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury. Ann. Thorac. Surg. 2003, 75:899-905.
40. Wynckel A., Randoux C., Millart H., Desroches C., Gillery P., Canivet E., et al. Kinetics of carbamylated haemoglobin in acute renal failure. Nephrol. Dial. Transplant. 2000, 15:1183-1188.
41. Parikh C.R., Jani A., Mishra J., Ma Q., Kelly C., Barasch J., et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant. 2006, 6:1639-1645.
42. Santamarina E., Penalba A., Garcia-Berrocoso T., Delgado P., Quintana M., Gonzalez-Alujas T., et al. Biomarker level improves the diagnosis of embolic source in ischemic stroke of unknown origin. J. Neurol. 2012, 259:2538-2545.
43. Hajdinjak E., Klemen P., Grmec S. Prognostic value of a single prehospital measurement of N-terminal pro-brain natriuretic peptide and troponin T after acute ischaemic stroke. J. Int. Med. Res. 2012, 40:768-776.
44. Fan J., Jouni H., Khaleghi M., Bailey K.R., Kullo I.J. Serum N-terminal pro-B-type natriuretic peptide levels are associated with functional capacity in patients with peripheral arterial disease. Angiology 2012, 63:435-442.
45. Jouni H., Rodeheffer R.J., Kullo I.J. Increased serum N-terminal pro-B-type natriuretic peptide levels in patients with medial arterial calcification and poorly compressible leg arteries. Arterioscler. Thromb. Vasc. Biol. 2011, 31:197-202.
46. Goei D., van Kuijk J.P., Flu W.J., Hoeks S.E., Chonchol M., Verhagen H.J., et al. Usefulness of repeated N-terminal pro-B-type natriuretic peptide measurements as incremental predictor for long-term cardiovascular outcome after vascular surgery. Am. J. Cardiol. 2011, 107:609-614.
47. Nicholson J.K., Wilson I.D. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. 2003, 2:668-676.
48. Want E.J., Nordstrom A., Morita H., Siuzdak G. From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J. Proteome Res. 2007, 6:459-468.
49. He W., Miao F.J., Lin D.C., Schwandner R.T., Wang Z., Gao J., et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 2004, 429:188-193.
50. Regard J.B., Sato I.T., Coughlin S.R. Anatomical profiling of G protein-coupled receptor expression. Cell 2008, 135:561-571.
51. Rhee E.P., Souza A., Farrell L., Pollak M.R., Lewis G.D., Steele D.J., et al. Metabolite profiling identifies markers of uremia. J. Am. Soc. Nephrol. 2010, 21:1041-1051.